{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:18:15Z","timestamp":1791242295380,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology"},{"name":"Luoyang Central Hospital Affiliated to Zhengzhou University"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijcard.2016.12.158","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T03:01:15Z","timestamp":1482980475000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["A meta-analysis of add-on use of spironolactone in patients with resistant hypertension"],"prefix":"10.1016","volume":"233","author":[{"given":"Di","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingshuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.12.158_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7473","article-title":"Resistant hypertension","volume":"345","author":"Myat","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0010","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(09)61600-7","article-title":"Resistant hypertension: an unmet treatment need","volume":"374","author":"Williams","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0015","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0020","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","article-title":"Renin: friend or foe?","volume":"93","author":"Brown","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0025","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","article-title":"Resistant hypertension: a review of diagnosis and management","volume":"311","author":"Vongpatanasin","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0030","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.tcm.2016.05.004","article-title":"Emerging concepts for patients with treatment-resistant hypertension","volume":"26","author":"Eirin","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0035","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0040","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0045","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0050","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in metaanalyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0065","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semnephrol.2014.04.004","article-title":"Role of aldosterone blockade in resistant hypertension","volume":"34","author":"Egan","year":"2014","journal-title":"Semin. Nephrol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.12.158_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002505","article-title":"Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: a 4-year follow-up","volume":"4","author":"Buglioni","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0080","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11906-016-0643-8","article-title":"New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension","volume":"18","author":"Narayan","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","article-title":"Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016","volume":"129","author":"Epstein","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5507\/bp.2012.078","article-title":"The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension","volume":"157","author":"Vaclavik","year":"2013","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/HJH.0000000000000870","article-title":"Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status","volume":"34","author":"Ghazi","year":"2016","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.158_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension","volume":"30","author":"Dudenbostel","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhh.2015.122","article-title":"Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology","volume":"30","author":"Denolle","year":"2016","journal-title":"J. Hum. Hypertens."},{"issue":"12","key":"10.1016\/j.ijcard.2016.12.158_bb0115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jch.12860","article-title":"Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension","volume":"18","author":"Eguchi","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension","volume":"4","author":"Engbaek","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.12.158_bb0145","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","article-title":"Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system","volume":"28","author":"Alvarez-Alvarez","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0150","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/jhh.2011.60","article-title":"Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease","volume":"26","author":"Pisoni","year":"2012","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/HJH.0b013e32835b71d6","article-title":"Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension","volume":"31","author":"Jansen","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0165","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0170","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/jhh.2014.64","article-title":"Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis","volume":"29","author":"Liu","year":"2015","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0180","first-page":"7270","article-title":"Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials","volume":"8","author":"Guo","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"4 SUPPL. 1","key":"10.1016\/j.ijcard.2016.12.158_bb0190","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.jash.2014.03.056","article-title":"Evaluation of the incidence of hyperkalemia in patients prescribed spironolactone for the treatment of resistant hypertension","volume":"8","author":"Chomicki","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2016.12.158_bb0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316321027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316321027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T08:55:03Z","timestamp":1536137703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316321027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":39,"alternative-id":["S0167527316321027"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.12.158","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727212599.793571588","asserted-by":"object"}]},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.12.158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}